Ontario and New Zealand Pharmaceuticals: Cost and Coverage

Ontario is a strong candidate for a comprehensive pharmacare program, given that it has a pre-existing public drug benefit program (the Ontario Drug Benefit Program [ODBP]). This paper outlines strategies from New Zealand's national pharmacare program (the Pharmaceutical Management Agency [PHAR...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelley, Leah T., Tenbensel, Tim, Johnson, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Longwoods Publishing 2018
Materias:
Discussion and Debate
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044260/
https://www.ncbi.nlm.nih.gov/pubmed/30052187
http://dx.doi.org/10.12927/hcpol.2018.25496
_version_ 1783339450904870912
author Kelley, Leah T.
Tenbensel, Tim
Johnson, Ana
author_facet Kelley, Leah T.
Tenbensel, Tim
Johnson, Ana
author_sort Kelley, Leah T.
collection PubMed
description Ontario is a strong candidate for a comprehensive pharmacare program, given that it has a pre-existing public drug benefit program (the Ontario Drug Benefit Program [ODBP]). This paper outlines strategies from New Zealand's national pharmacare program (the Pharmaceutical Management Agency [PHARMAC]) and compares these strategies to other international examples. It is recommended that the ODBP engage in three strategies currently utilized by the PHARMAC to achieve significant cost savings and create potential to increase their insurance coverage: (i) strict budgeting; (ii) tendering and negotiating; and (iii) reference pricing.
format Online
Article
Text
id pubmed-6044260
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Longwoods Publishing
record_format MEDLINE/PubMed
spelling pubmed-60442602019-05-01 Ontario and New Zealand Pharmaceuticals: Cost and Coverage Kelley, Leah T. Tenbensel, Tim Johnson, Ana Healthc Policy Discussion and Debate Ontario is a strong candidate for a comprehensive pharmacare program, given that it has a pre-existing public drug benefit program (the Ontario Drug Benefit Program [ODBP]). This paper outlines strategies from New Zealand's national pharmacare program (the Pharmaceutical Management Agency [PHARMAC]) and compares these strategies to other international examples. It is recommended that the ODBP engage in three strategies currently utilized by the PHARMAC to achieve significant cost savings and create potential to increase their insurance coverage: (i) strict budgeting; (ii) tendering and negotiating; and (iii) reference pricing. Longwoods Publishing 2018-05 /pmc/articles/PMC6044260/ /pubmed/30052187 http://dx.doi.org/10.12927/hcpol.2018.25496 Text en Copyright © 2018 Longwoods Publishing http://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 License, which permits rights to copy and redistribute the work for non-commercial purposes only, provided the original work is given proper attribution.
spellingShingle Discussion and Debate
Kelley, Leah T.
Tenbensel, Tim
Johnson, Ana
Ontario and New Zealand Pharmaceuticals: Cost and Coverage
title Ontario and New Zealand Pharmaceuticals: Cost and Coverage
title_full Ontario and New Zealand Pharmaceuticals: Cost and Coverage
title_fullStr Ontario and New Zealand Pharmaceuticals: Cost and Coverage
title_full_unstemmed Ontario and New Zealand Pharmaceuticals: Cost and Coverage
title_short Ontario and New Zealand Pharmaceuticals: Cost and Coverage
title_sort ontario and new zealand pharmaceuticals: cost and coverage
topic Discussion and Debate
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044260/
https://www.ncbi.nlm.nih.gov/pubmed/30052187
http://dx.doi.org/10.12927/hcpol.2018.25496
work_keys_str_mv AT kelleyleaht ontarioandnewzealandpharmaceuticalscostandcoverage
AT tenbenseltim ontarioandnewzealandpharmaceuticalscostandcoverage
AT johnsonana ontarioandnewzealandpharmaceuticalscostandcoverage

Ejemplares similares